The Skilled Nursing Facility (SNF) Portfolio and Tenant Transitions

Despite the excitement surrounding the SHOP expansion, the legacy Skilled Nursing Facility (SNF) portfolio remains a critical cash cow, comprising roughly $2.8 billion in assets and generating a healthy cash NOI yield on gross book value of 9.9%.

The primary health indicator for a triple-net leased asset is EBITDARM Coverage. EBITDARM stands for Earnings Before Interest, Taxes, Depreciation, Amortization, Rent, and Management fees. It measures the tenant operator's cash flow relative to the rent they owe the REIT. A ratio of 1.0x means the tenant is earning exactly enough to pay rent, with zero margin for error. As of Q3 2026, Sabra’s Skilled Nursing/Transitional Care portfolio posted an EBITDARM coverage ratio of 2.52x [cite: 1, 7]. This provides a massive margin of safety. Operators are generating $2.52 for every $1.00 of rent owed, indicating highly stable operations and virtually eliminating near-term rent default risk across the stabilized tenant base. Meanwhile, Leased Senior Housing generated 1.58x coverage, and Specialty Hospitals stood at an exceptional 3.91x coverage [cite: 1, 7].

However, Sabra has had to proactively manage distressed tenants to achieve this stability, best illustrated by the ongoing Avamere restructuring. Avamere, historically one of Sabra’s largest legacy tenants (representing roughly 8.4% of annualized cash NOI), faced severe operational pressures [cite: 8]. Sabra recognized this distress early and engineered a comprehensive transition.

Effective October 1, 2026, Sabra successfully transitioned 26 properties formerly leased by Avamere to two robust replacement operators: 22 properties to subsidiaries of Cascadia Healthcare and four properties to subsidiaries of the Ensign Group [cite: 2, 9]. By restructuring these leases and transitioning the operations, Sabra negotiated an increase in combined annualized cash rent from an initial base of $41 million (and a stabilized $48 million) up to a new baseline of $53 million [cite: 2, 6, 16]. While only three months of this elevated $53 million run-rate will be captured in 2026, the full annual impact will heavily benefit 2027 NOI by generating a year-over-year earnings step-up of roughly $5 million.

It is worth noting that this transition resulted in a Q3 accounting write-off of $6.2 million [cite: 1, 17] in straight-line rent receivables and lease intangibles. Straight-line rent is an accounting convention that averages out escalating rent payments over the life of a lease; when a lease is terminated early, as with Avamere, those non-cash receivables must be written off. Management accurately normalized this item out of its AFFO calculations, as it does not reflect cash operating performance.

(function(){var b=document.getElementById(‘gold-sticky-2-close');if(b){b.addEventListener(‘click',function(){var p=document.getElementById(‘gold-sticky-2′);if(p)p.style.display='none';})}})();

Looking forward, management highlighted that almost half of Sabra's SNF NOI comes from leases that mature through 2031 [cite: 16]. Because current tenant coverage is exceptionally strong (2.52x), management holds substantial leverage to execute “mark-to-market” rent resets upon lease expiration. Instead of the standard 2.5% annual escalators, Sabra expects to negotiate meaningful rent bumps across the SNF portfolio, utilizing these assets as a steady yield engine to fund the SHOP expansion [cite: 13, 17].

Capital Structure, Liquidity, and Debt Maturities

Aggressive portfolio transitions require pristine balance sheets. The commercial real estate industry is heavily penalized by capital markets when leverage scales uncontrollably during acquisition sprees. Sabra, however, has engineered its growth while simultaneously deleveraging.

At the close of Q3 2026, Sabra reported a Net Debt to Adjusted EBITDA ratio of 4.54x, a sequential improvement from 4.61x in the prior quarter [cite: 1, 3]. For a healthcare REIT, a leverage ratio below 5.0x is universally considered investment-grade territory, providing a wide buffer against debt covenant breaches.

Sabra maintains robust liquidity, totaling approximately $1.2 billion [cite: 1, 18]. This liquidity tranche is comprised of $36.2 million in unrestricted cash, $873.5 million available on its revolving credit facility, and uniquely, $292.5 million tethered to its At-The-Market (ATM) forward equity program [cite: 10, 18].

The ATM forward program is a highly sophisticated capital markets tool that Sabra has wielded effectively. Instead of issuing large, dilutive blocks of secondary equity all at once, an ATM program allows the REIT to “drip” shares into the open market at prevailing market prices. The “forward” feature is even more strategic: Sabra can lock in a share price today but delay the actual issuance and settlement of the shares for up to a year.

As of September 30, 2026, Sabra had 15.0 million shares outstanding under forward sale agreements at a weighted average net price of $19.53 per share [cite: 1, 10]. During Q3 alone, Sabra settled 6.5 million of these shares, generating $116.2 million in net proceeds, which were subsequently weaponized to fund the $222.8 million in SHOP acquisitions closed during the quarter [cite: 2, 13]. This mechanism allows Sabra to perfectly match its equity funding with its acquisition pipeline, neutralizing the earnings dilution that typically plagues REITs when they hold idle cash.

Regarding debt maturities, Sabra faces a manageable schedule but carries near-term refinancing obligations in 2027. The company's weighted average maturity is approximately 4 years [cite: 8] with an effective interest rate hovering near 4.01% [cite: 8]. The most immediate hurdle is the $317.5 million revolving credit facility, which technically matures in January 2027 (though it contains extension options), alongside $100 million of 5.38% unsecured notes due in May 2027. Given Sabra’s 4.54x leverage profile and massive undrawn revolver capacity, these maturities do not present a systemic risk, and the company maintains ample flexibility to refinance in the unsecured bond market.

Dividend Policy, Safety, and Yield Analysis

For institutional income investors and retail shareholders alike, the dividend acts as the gravitational anchor for REIT valuation. Sabra’s Board of Directors declared a Q3 2026 cash dividend of $0.30 per share (annualized at $1.20), payable on November 30, 2026 [cite: 1, 18]. At prevailing market prices near $20.00, this equates to an attractive forward dividend yield of approximately 6.0% (precise metrics tracking 5.11% to 6.0% depending on exact entry point) [cite: 19, 20].

The safety of a REIT dividend is exclusively evaluated through the lens of the AFFO payout ratio. Traditional GAAP payout ratios (which divide dividends by Net Income) are fundamentally flawed in real estate analysis due to depreciation.

Based on Q3 Normalized AFFO of $0.41, Sabra’s $0.30 dividend represents a highly secure 73% payout ratio [cite: 1]. In the REIT ecosystem, payout ratios below 80% are considered exceptionally safe. A 73% ratio allows Sabra to retain roughly 27% of its internally generated cash flow to fund renovations, execute minor acquisitions, and pay down debt organically without returning to the capital markets.

Furthermore, based on the newly raised 2026 full-year AFFO guidance midpoint of $1.605 [cite: 1], the $1.20 annual dividend yields an annualized payout ratio of roughly 75% [cite: 8, 20]. This indicates that the dividend is insulated against localized operational shocks. While Sabra has held the dividend flat at $1.20 since 2023, the compression in the payout ratio (as AFFO grows while the dividend remains static) suggests that management is prioritizing balance sheet strength and SHOP expansion over immediate distribution hikes [cite: 8]. If FFO and AFFO continue compounding at current 7% to 8% trajectories, a dividend increase may be mathematically inevitable by late 2027 to comply with IRS regulations requiring REITs to distribute at least 90% of taxable income.

Valuation Analysis: Peer Comparables and Market Pricing

Sabra’s valuation requires benchmarking against its closest healthcare REIT peers, primarily CareTrust REIT (CTRE), Omega Healthcare Investors (OHI), and Ashford Hospitality Trust (AHT, as a proxy for operational intensive assets).

The preeminent metric for REIT valuation is the Price-to-AFFO (P/AFFO) and Price-to-FFO (P/FFO) multiples, alongside intrinsic assessments against Net Asset Value (NAV). To provide a comprehensive evaluation, the table below synthesizes the competitive landscape using standardized financial markers.

Peer Comparison Matrix: Healthcare REITs

| Metric | Sabra Health Care (SBRA) | Omega Healthcare (OHI) | CareTrust REIT (CTRE) | | :— | :— | :— | :— | | Price / FFO Multiple | 13.7x [cite: 19] | 16.4x [cite: 21, 22] | 16.0x (to 12.8x) [cite: 20, 23] | | Price / AFFO Multiple | 14.8x [cite: 19, 20] | N/A (Trading at Premium) | 13.9x [cite: 20] | | Dividend Yield | 5.11% – 6.0% [cite: 19] | 5.62% – 5.8% [cite: 22, 24] | 4.22% – 5.63% [cite: 20, 23] | | AFFO Payout Ratio | 73.0% – 75.8% [cite: 1, 20] | 97.14% [cite: 22, 24] | 70.0% – 78.0% [cite: 20, 23] | | Leverage (Net Debt/EBITDA) | 4.54x (or 5.4x) [cite: 3, 20] | Lowest in Company History [cite: 21] | 1.01x run-rate (or 5.6x) [cite: 20, 25] | | Premium / Discount to NAV | -9.3% Discount [cite: 5, 20] | Modest Premium [cite: 24, 26] | -9.2% Discount [cite: 20] |

Sabra (SBRA): Trades at roughly 14.8x trailing P/AFFO and between 13.7x to 14.5x forward P/FFO based on 2026 guidance [cite: 19, 20]. Omega Healthcare (OHI): Trades at a richer multiple of 16.4x P/FFO, yielding approximately 5.62% to 5.79% [cite: 22, 24]. CareTrust REIT (CTRE): Commands a 13.9x P/AFFO multiple [cite: 20], offering a lower yield profile near 4.22% to 5.63% depending on entry price [cite: 20, 23].

Sabra sits securely in the middle of this cohort. It trades at a discount to Omega Healthcare Investors, despite Omega operating with a much more dangerous dividend payout ratio (OHI distributes over 87% of cash flow and 97.14% of basic earnings, creating extreme vulnerability) [cite: 22, 24]. Sabra’s lower payout ratio (75%) and higher yield (6.0%) present a compelling arbitrage opportunity relative to OHI.

Furthermore, real estate equity can be evaluated through the lens of Net Asset Value (NAV)—the private-market appraisal value of the physical properties minus debt. Private market models and institutional consensus, including S&P Global Market Intelligence and REITwave, estimate that Sabra currently trades at a ~9.3% discount to its intrinsic NAV [cite: 5, 19, 20]. This implies that investors are currently able to purchase Sabra’s underlying real estate portfolio on the public market for 90 cents on the dollar, offering a margin of safety against potential cap rate expansion.

Risks, Red Flags, and Open Questions

While the Q3 narrative is undeniably bullish, deep-dive analysis uncovers a severe red flag embedded in Sabra's legacy loan portfolio, alongside macroeconomic vulnerabilities intrinsic to the SHOP transition.

The Recovery Centers of America (RCA) $100 Million Write-Off & Remaining Loan Book

The most glaring blemish on Sabra's 2026 ledger is the catastrophic outcome of its mortgage loan to Recovery Centers of America (RCA). Sabra originated a $300 million mortgage loan to RCA, effectively acting as a direct lender in the behavioral health sector. In mid-2026, Sabra agreed to accept a reduced cash payoff of $200 million to settle the obligation, resulting in a staggering $100 million write-off [cite: 8, 27].

This non-cash provision permanently impaired asset value and severely depressed Sabra’s YTD GAAP net income, which plummeted from $128.4 million in 2025 to just $44.3 million in the first nine months of 2026 [cite: 2, 6]. While management points out that recovering the $200 million allowed them to pay down the revolving credit facility and lower Net Debt to EBITDA to 4.54x, this explanation glosses over a fundamental failure in underwriting. A 33% loss of principal on a primary mortgage loan indicates severe miscalculations regarding the borrower's creditworthiness and the underlying asset's collateral value.

The open question for institutional investors is contagion risk across the remaining portfolio. Following the RCA settlement and other repayments, Sabra still maintains between $115.1 million and $120.3 million in outstanding loan receivables [cite: 8, 28]. This residual book consists of 11 unique investments: two mortgage loans and nine other loans [cite: 2]. The largest components include a $29 million mortgage to Specialty Hospitals (carrying an 11.5% interest rate) and nine other loans aggregating to $30.5 million (carrying a weighted average contractual interest rate of 6.7%) [cite: 2].

If the underwriting standards that approved the RCA loan were applied to the remaining loan book, further impairments cannot be ruled out. Concerningly, two of these outstanding loan investments are currently sitting on nonaccrual status with a book value of zero, and one additional $1.2 million principal loan exhibits deteriorated credit quality [cite: 27, 29]. While Sabra’s behavioral health and specialty hospital tenants demonstrate a massive 3.91x EBITDARM coverage [cite: 7], the nonaccrual status of existing loans highlights that capital destruction serves as a stark warning regarding the REIT's ability to operate successfully as a specialty lender.

Operational Leverage and Inflationary Pressures in SHOP

The transition to a 50% SHOP portfolio is a double-edged sword. While it currently allows Sabra to capture the 7.3% growth in RevPOR, it simultaneously exposes the REIT to raw healthcare labor inflation.

In a triple-net lease, if nursing wages spike 10%, the tenant operator absorbs the hit. In a SHOP structure, Sabra absorbs the hit. While ExPOR (Expenses Per Occupied Room) grew by a manageable 4.7% in Q3, driven by repairs, marketing, and incentive fees [cite: 13, 14], healthcare labor remains chronically tight. A resurgence in clinical wage inflation, or an unexpected spike in property insurance premiums, would compress Sabra’s best-in-class 34.9% margin instantly. Success in SHOP requires flawless execution from Sabra's third-party operating partners.

Capitalization and Dilution Overhang

Finally, while the ATM forward equity program is brilliant for matching funding with acquisitions, it represents a looming dilution overhang. Sabra has 15.0 million shares outstanding under forward contracts [cite: 1, 10]. While they have locked in the pricing ($19.53), the physical issuance of these shares over the coming quarters will increase the total share count [cite: 1, 10]. Consequently, total FFO must grow faster than the share count expands to ensure that per-share* metrics do not stagnate.

Synthesis

Sabra Health Care REIT is fundamentally derisking its balance sheet while pivoting toward the highest-growth segment in real estate. The Q3 2026 results confirm that the transition is working: occupancy is climbing, pricing power is outstripping expense growth, and the 73% dividend payout ratio confirms the underlying health of the cash engine [cite: 1, 13]. The transition of the distressed Avamere assets to stronger operators effectively removes the largest overhang from the legacy triple-net portfolio, leaving a highly covered (2.52x EBITDARM) skilled nursing portfolio to act as a funding mechanism for future growth [cite: 9, 13].

However, the $100 million RCA mortgage write-off is a sobering reminder of the risks associated with non-core capital deployment. Sabra is trading at a 9.3% discount to NAV and offers a superior valuation proposition compared to peers like Omega Healthcare Investors, provided management avoids further lending missteps. If Sabra can successfully digest the $1.17 billion in newly acquired and awarded SHOP properties without suffering margin degradation, the equity is positioned for sustained structural outperformance into 2027.

Sources: 1. fool.com 2. stocktitan.net 3. investing.com 4. reitwave.com 5. spglobal.com 6. stocktitan.net 7. businesswire.com 8. crowdfundedwealth.com 9. skillednursingnews.com 10. stocktitan.net 11. tradingview.com 12. gurufocus.com 13. marketbeat.com 14. tradingkey.com 15. seniorhousingnews.com 16. q4cdn.com 17. gurufocus.com 18. nasdaq.com 19. reitwave.com 20. reitwave.com 21. 247wallst.com 22. marketbeat.com 23. hoyacapital.com 24. gurufocus.com 25. crowdfundedwealth.com 26. investing.com 27. cloudfront.net 28. kalkinemedia.com 29. cloudfront.net

For informational purposes only; not investment advice.